Amifostine

Drug Profile

Amifostine

Alternative Names: Ethiofos; Ethyol; Gammaphos; NSC 296961; WR 2721; YM 08310

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Southern Research Institute
  • Developer MedImmune Oncology
  • Class Chemoprotectants; Organothiophosphorus compounds; Small molecules
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Radioprotection; Chemoprotection; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemoprotection; Radioprotection
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 10 May 2016 Clinigen and Cumberland Pharmaceuticals enter into an agreement for commercialisation of amifostine in USA
  • 20 Aug 2014 Clinigen acquires global right to amifostine from AstraZeneca (MedImmune)
  • 29 Jan 2008 Discontinued - Clinical-Phase-Unknown for Radioprotection in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top